Stanisław Sław S. Gõźdź-rekin lankidetzan egindako argitalpenak (53)

2021

  1. The histology of brain tumors for 67 331 children and 671 085 adults diagnosed in 60 countries during 2000-2014: a global, population-based study (CONCORD-3)

    Neuro-Oncology, Vol. 23, Núm. 10, pp. 1765-1776

2020

  1. Endocrine treatment and incidence of relapse in women with oestrogen receptor-positive breast cancer in Europe: a population-based study

    Breast Cancer Research and Treatment, Vol. 183, Núm. 2, pp. 439-450

  2. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study

    Archives of Gynecology and Obstetrics, Vol. 301, Núm. 2, pp. 591-602

2019

  1. Epidemiology of rare cancers and inequalities in oncologic outcomes

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 3-11

  2. Mesothelioma and thymic tumors: Treatment challenges in (outside) a network setting

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 75-80

  3. Testicular germ-cell tumours and penile squamous cell carcinoma: Appropriate management makes the difference

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 60-66

  4. Treatment challenges in and outside a network setting: Head and neck cancers

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 40-45

  5. Treatment challenges in and outside a network setting: Soft tissue sarcomas

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 31-39

  6. Treatment challenges in and outside a specialist network setting: Pancreatic neuroendocrine tumours

    European Journal of Surgical Oncology, Vol. 45, Núm. 1, pp. 46-51

2018

  1. Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

    The Lancet, Vol. 391, Núm. 10125, pp. 1023-1075

2017

  1. Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study

    The Lancet Oncology, Vol. 18, Núm. 8, pp. 1022-1039

  2. Data quality in rare cancers registraton: The report of the RARECARE data quality study

    Tumori, Vol. 103, Núm. 1, pp. 22-32

  3. Erratum to “The histology of ovarian cancer: Worldwide distribution and implications for international survival comparisons (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 405–413](S0090825816314974)(10.1016/j.ygyno.2016.10.019)

    Gynecologic Oncology

  4. Erratum to “Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)” [Gynecol. Oncol. 144 (2017) 396–404](S009082581631575X)(10.1016/j.ygyno.2016.11.019)

    Gynecologic Oncology

  5. Geographical variability in survival of European children with central nervous system tumours

    European Journal of Cancer, Vol. 82, pp. 137-148

  6. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study

    European Journal of Cancer, Vol. 84, pp. 335-353

  7. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5

    European Journal of Cancer, Vol. 77, pp. 140-152

  8. The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)

    Gynecologic Oncology, Vol. 144, Núm. 2, pp. 405-413

  9. Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)

    Gynecologic Oncology, Vol. 144, Núm. 2, pp. 396-404

  10. Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries

    The Lancet Haematology, Vol. 4, Núm. 5, pp. e202-e217